Selected research
Industry Growth & Trends
Global Tuberculosis Vaccine Drug Industry Growth and Trends Forecast to 2032
Market perspective
The global Tuberculosis Vaccine Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Tuberculosis Vaccine Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Tuberculosis Vaccine Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Tuberculosis Vaccine Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Tuberculosis Vaccine Drug include Merck, Taj Pharmaceuticals, Serum Institute of India, Queen Saovabha Mem. Inst, Microgen, Japan BCG Lab, IVAC, GreenSignal Bio Pharma and China National Biotec, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Tuberculosis Vaccine Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Tuberculosis Vaccine Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Tuberculosis Vaccine Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Tuberculosis Vaccine Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Tuberculosis Vaccine Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Tuberculosis Vaccine Drug Market by Company
Merck
Taj Pharmaceuticals
Serum Institute of India
Queen Saovabha Mem. Inst
Microgen
Japan BCG Lab
IVAC
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
BioFarma
Ataulpho de Paiva
AJ Vaccines
Tuberculosis Vaccine Drug Segment by Type
Immune Vaccine
Therapy Vaccine
Tuberculosis Vaccine Drug Segment by Application
Self-Procurement
UNICEF
Other
Tuberculosis Vaccine Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccine Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccine Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccine Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tuberculosis Vaccine Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Tuberculosis Vaccine Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immune Vaccine
- Therapy Vaccine
Applications
- Self-Procurement
- UNICEF
- Other
Companies covered
- Merck
- Taj Pharmaceuticals
- Serum Institute of India
- Queen Saovabha Mem. Inst
- Microgen
- Japan BCG Lab
- IVAC
- GreenSignal Bio Pharma
- China National Biotec
- Biomed Lublin
- BioFarma
- Ataulpho de Paiva
- AJ Vaccines
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Tuberculosis Vaccine Drug Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Tuberculosis Vaccine Drug Sales Estimates and Forecasts (2021-2032)
- 1.3 Tuberculosis Vaccine Drug Market by Type
- 1.3.1 Immune Vaccine
- 1.3.2 Therapy Vaccine
- 1.4 Global Tuberculosis Vaccine Drug Market Size by Type
- 1.4.1 Global Tuberculosis Vaccine Drug Market Size Overview by Type (2021-2032)
- 1.4.2 Global Tuberculosis Vaccine Drug Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Tuberculosis Vaccine Drug Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Tuberculosis Vaccine Drug Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Tuberculosis Vaccine Drug Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Tuberculosis Vaccine Drug Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Tuberculosis Vaccine Drug Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Tuberculosis Vaccine Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Tuberculosis Vaccine Drug Industry Trends
- 2.2 Tuberculosis Vaccine Drug Industry Drivers
- 2.3 Tuberculosis Vaccine Drug Industry Opportunities and Challenges
- 2.4 Tuberculosis Vaccine Drug Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Tuberculosis Vaccine Drug Revenue (2021-2026)
- 3.2 Global Top Players by Tuberculosis Vaccine Drug Sales (2021-2026)
- 3.3 Global Top Players by Tuberculosis Vaccine Drug Price (2021-2026)
- 3.4 Global Tuberculosis Vaccine Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Tuberculosis Vaccine Drug Major Company Production Sites & Headquarters
- 3.6 Global Tuberculosis Vaccine Drug Company, Product Type & Application
- 3.7 Global Tuberculosis Vaccine Drug Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Tuberculosis Vaccine Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Tuberculosis Vaccine Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Tuberculosis Vaccine Drug Tier 1, Tier 2, and Tier 3
4 Tuberculosis Vaccine Drug Regional Status and Outlook
- 4.1 Global Tuberculosis Vaccine Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Tuberculosis Vaccine Drug Historic Market Size by Region
- 4.2.1 Global Tuberculosis Vaccine Drug Sales in Volume by Region (2021-2026)
- 4.2.2 Global Tuberculosis Vaccine Drug Sales in Value by Region (2021-2026)
- 4.2.3 Global Tuberculosis Vaccine Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Tuberculosis Vaccine Drug Forecasted Market Size by Region
- 4.3.1 Global Tuberculosis Vaccine Drug Sales in Volume by Region (2027-2032)
- 4.3.2 Global Tuberculosis Vaccine Drug Sales in Value by Region (2027-2032)
- 4.3.3 Global Tuberculosis Vaccine Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Tuberculosis Vaccine Drug by Application
- 5.1 Tuberculosis Vaccine Drug Market by Application
- 5.1.1 Self-Procurement
- 5.1.2 UNICEF
- 5.1.3 Other
- 5.2 Global Tuberculosis Vaccine Drug Market Size by Application
- 5.2.1 Global Tuberculosis Vaccine Drug Market Size Overview by Application (2021-2032)
- 5.2.2 Global Tuberculosis Vaccine Drug Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Tuberculosis Vaccine Drug Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Tuberculosis Vaccine Drug Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Tuberculosis Vaccine Drug Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Tuberculosis Vaccine Drug Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Tuberculosis Vaccine Drug Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Tuberculosis Vaccine Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Merck
- 6.1.1 Merck Company Information
- 6.1.2 Merck Business Overview
- 6.1.3 Merck Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Merck Tuberculosis Vaccine Drug Product Portfolio
- 6.1.5 Merck Recent Developments
- 6.2 Taj Pharmaceuticals
- 6.2.1 Taj Pharmaceuticals Company Information
- 6.2.2 Taj Pharmaceuticals Business Overview
- 6.2.3 Taj Pharmaceuticals Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Taj Pharmaceuticals Tuberculosis Vaccine Drug Product Portfolio
- 6.2.5 Taj Pharmaceuticals Recent Developments
- 6.3 Serum Institute of India
- 6.3.1 Serum Institute of India Company Information
- 6.3.2 Serum Institute of India Business Overview
- 6.3.3 Serum Institute of India Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Serum Institute of India Tuberculosis Vaccine Drug Product Portfolio
- 6.3.5 Serum Institute of India Recent Developments
- 6.4 Queen Saovabha Mem. Inst
- 6.4.1 Queen Saovabha Mem. Inst Company Information
- 6.4.2 Queen Saovabha Mem. Inst Business Overview
- 6.4.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Drug Product Portfolio
- 6.4.5 Queen Saovabha Mem. Inst Recent Developments
- 6.5 Microgen
- 6.5.1 Microgen Company Information
- 6.5.2 Microgen Business Overview
- 6.5.3 Microgen Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Microgen Tuberculosis Vaccine Drug Product Portfolio
- 6.5.5 Microgen Recent Developments
- 6.6 Japan BCG Lab
- 6.6.1 Japan BCG Lab Company Information
- 6.6.2 Japan BCG Lab Business Overview
- 6.6.3 Japan BCG Lab Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Japan BCG Lab Tuberculosis Vaccine Drug Product Portfolio
- 6.6.5 Japan BCG Lab Recent Developments
- 6.7 IVAC
- 6.7.1 IVAC Company Information
- 6.7.2 IVAC Business Overview
- 6.7.3 IVAC Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 IVAC Tuberculosis Vaccine Drug Product Portfolio
- 6.7.5 IVAC Recent Developments
- 6.8 GreenSignal Bio Pharma
- 6.8.1 GreenSignal Bio Pharma Company Information
- 6.8.2 GreenSignal Bio Pharma Business Overview
- 6.8.3 GreenSignal Bio Pharma Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 GreenSignal Bio Pharma Tuberculosis Vaccine Drug Product Portfolio
- 6.8.5 GreenSignal Bio Pharma Recent Developments
- 6.9 China National Biotec
- 6.9.1 China National Biotec Company Information
- 6.9.2 China National Biotec Business Overview
- 6.9.3 China National Biotec Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 China National Biotec Tuberculosis Vaccine Drug Product Portfolio
- 6.9.5 China National Biotec Recent Developments
- 6.10 Biomed Lublin
- 6.10.1 Biomed Lublin Company Information
- 6.10.2 Biomed Lublin Business Overview
- 6.10.3 Biomed Lublin Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 Biomed Lublin Tuberculosis Vaccine Drug Product Portfolio
- 6.10.5 Biomed Lublin Recent Developments
- 6.11 BioFarma
- 6.11.1 BioFarma Company Information
- 6.11.2 BioFarma Business Overview
- 6.11.3 BioFarma Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 BioFarma Tuberculosis Vaccine Drug Product Portfolio
- 6.11.5 BioFarma Recent Developments
- 6.12 Ataulpho de Paiva
- 6.12.1 Ataulpho de Paiva Company Information
- 6.12.2 Ataulpho de Paiva Business Overview
- 6.12.3 Ataulpho de Paiva Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 Ataulpho de Paiva Tuberculosis Vaccine Drug Product Portfolio
- 6.12.5 Ataulpho de Paiva Recent Developments
- 6.13 AJ Vaccines
- 6.13.1 AJ Vaccines Company Information
- 6.13.2 AJ Vaccines Business Overview
- 6.13.3 AJ Vaccines Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 AJ Vaccines Tuberculosis Vaccine Drug Product Portfolio
- 6.13.5 AJ Vaccines Recent Developments
7 North America by Country
- 7.1 North America Tuberculosis Vaccine Drug Sales by Country
- 7.1.1 North America Tuberculosis Vaccine Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Tuberculosis Vaccine Drug Sales by Country (2021-2026)
- 7.1.3 North America Tuberculosis Vaccine Drug Sales Forecast by Country (2027-2032)
- 7.2 North America Tuberculosis Vaccine Drug Market Size by Country
- 7.2.1 North America Tuberculosis Vaccine Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Tuberculosis Vaccine Drug Market Size by Country (2021-2026)
- 7.2.3 North America Tuberculosis Vaccine Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Tuberculosis Vaccine Drug Sales by Country
- 8.1.1 Europe Tuberculosis Vaccine Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Tuberculosis Vaccine Drug Sales by Country (2021-2026)
- 8.1.3 Europe Tuberculosis Vaccine Drug Sales Forecast by Country (2027-2032)
- 8.2 Europe Tuberculosis Vaccine Drug Market Size by Country
- 8.2.1 Europe Tuberculosis Vaccine Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Tuberculosis Vaccine Drug Market Size by Country (2021-2026)
- 8.2.3 Europe Tuberculosis Vaccine Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Tuberculosis Vaccine Drug Sales by Country
- 9.1.1 Asia-Pacific Tuberculosis Vaccine Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Tuberculosis Vaccine Drug Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Tuberculosis Vaccine Drug Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Tuberculosis Vaccine Drug Market Size by Country
- 9.2.1 Asia-Pacific Tuberculosis Vaccine Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Tuberculosis Vaccine Drug Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Tuberculosis Vaccine Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Tuberculosis Vaccine Drug Sales by Country
- 10.1.1 South America Tuberculosis Vaccine Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Tuberculosis Vaccine Drug Sales by Country (2021-2026)
- 10.1.3 South America Tuberculosis Vaccine Drug Sales Forecast by Country (2027-2032)
- 10.2 South America Tuberculosis Vaccine Drug Market Size by Country
- 10.2.1 South America Tuberculosis Vaccine Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Tuberculosis Vaccine Drug Market Size by Country (2021-2026)
- 10.2.3 South America Tuberculosis Vaccine Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Tuberculosis Vaccine Drug Sales by Country
- 11.1.1 Middle East and Africa Tuberculosis Vaccine Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Tuberculosis Vaccine Drug Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Tuberculosis Vaccine Drug Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Tuberculosis Vaccine Drug Market Size by Country
- 11.2.1 Middle East and Africa Tuberculosis Vaccine Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Tuberculosis Vaccine Drug Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Tuberculosis Vaccine Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Tuberculosis Vaccine Drug Value Chain Analysis
- 12.1.1 Tuberculosis Vaccine Drug Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Tuberculosis Vaccine Drug Production Mode & Process
- 12.2 Tuberculosis Vaccine Drug Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Tuberculosis Vaccine Drug Distributors
- 12.2.3 Tuberculosis Vaccine Drug Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst